Liver X receptors (LXRs) are implicated in the regulation of cholesterol homeostasis, inflammatory response and atherogenesis. Administration of LXR agonists inhibits the progress of atherosclerosis, and also increases plasma triglyceride levels, representing an obstacle to their use in treating this disease. The objective of this study was to develop an alternative approach that could overcome this obstacle. Eight-week-old low-density lipoprotein receptor-deficient (LDLR À/À ) mice were transplanted with hematopoietic stem cell (HSC)-enriched bone marrow cells transduced with lentivectors expressing either green fluorescent protein (GFP) (Lenti-SP-GFP, control) or LXRa (Lenti-SP-LXRa) driven by a synthetic macrophage promoter. At 4 weeks post-transplant, the mice were fed with a Western diet for 8 weeks and then killed. Compared with Lenti-SP-GFP mice, the Lenti-SP-LXRa mice had a 30% reduction in atherosclerotic lesions, which was accompanied by increases in levels of macrophage expression of cholesterol efflux genes apolipoprotein E and ATP-binding cassette A1, as well as decreases in plasma inflammatory cytokines interleukin-6 and tumor necrosis factor-a. Intriguingly, a 50% reduction of plasma triglyceride level was also observed. We conclude that HSC-based macrophage LXRa gene therapy ameliorates the development of atherosclerosis along with an unexpected concomitant reduction of plasma triglyceride levels in LDLR À/À mice. These findings highlight the potential value of macrophage LXR expression as an avenue for therapeutic intervention against atherosclerosis.
INTRODUCTION
Liver X receptors a and b (LXRa and LXRb), members of the nuclear receptor transcription factor superfamily, are master regulators of whole-body cholesterol homeostasis, as well as metabolic and inflammatory signaling integration. 1, 2 The LXR transcription factors, forming obligate heterodimers with the retinoid X receptor (RXR), regulate target gene expression through interaction with LXR response elements in the regulatory regions of these genes. The internal ligands for LXRs are oxidized derivatives of cholesterol (oxysterols). LXRa is highly expressed in the liver and selectively at lower levels in other tissues involved in lipid homeostasis, such as intestine, adipocytes and macrophages, whereas LXRb is expressed ubiquitously. 1 It is generally believed that the two isoforms can compensate for each other in biological activity. 3, 4 Ligand activation of the LXRs decreases intestinal cholesterol absorption efficiency, induces cholesterol efflux from lipidladen macrophages and negatively regulates inflammatory gene expression, suggesting a beneficial effect on the development of cardiovascular disease. Direct evidence for a role of the LXR pathway in atherosclerosis susceptibility has been obtained from studies using genetically modified mice. Apolipoprotein E-deficient (apoE À/À ) or low-density lipoprotein receptor-deficient (LDLR À/À ) mice transplanted with bone marrow cells from LXRa/b double-knockout (LXRa/b À/À ) animals exhibited significantly greater atherosclerotic lesion development than their counterparts receiving bone marrow cells from wild-type mice. 5 In addition, LXRa/b À/À mice exhibit increased cholesterol accumulation in arterial wall macrophages even on normal chow diets. Consistently, activation of LXRs by synthetic agonists provides protection against lesion development and leads to regression of established lesions in mouse models. 6, 7 However, administration of synthetic LXR agonists triggers induction of the hepatic lipogenic pathway and causes hypertriglyceridemia. This undesirable effect is a significant obstacle in the development of LXR agonists as potential drugs. 8, 9 Atherosclerosis is a disorder of lipid metabolism, as well as a chronic inflammatory disease. 10 Macrophages, participating in both lipid metabolism and inflammation, are intimately involved in all phases of atherosclerosis, from development of the fatty streak to processes that ultimately contribute to plaque rupture and myocardial infarction. 11 Macrophage expression of certain genes is atheroprotective, whereas inadequate expression or lack of expression of these same genes in macrophages increases atherosclerosis. 12 It has been reported that macrophage LXRa is required for antiatherogenic activity of LXRa agonists. 7 We hypothesized that macrophage-specific overexpression of LXRa would lead to the reduction of atherosclerosis without elevation of liver-derived plasma triglycerides, an adverse effect associated with synthetic LXR agonist treatment. Using the macrophage-specific promoter/lentiviral system we developed previously, 13 bone marrow stem cells were manipulated to express transgenic LXRa when differentiated into macrophages in LDLR À/À mice. Our results show that this approach can not only efficiently ameliorate the development of atherosclerosis, but can also reduce plasma triglyceride levels in vivo. Transgenic LXR expression in macrophages may provide a promising method for future intervention in this highly prevalent human disease.
RESULTS

Enhanced expression of LXRa and its target genes in macrophages
To validate the lentiviral constructs and test their effects on target genes, the macrophage cell line RAW 264.7 (data not shown) and bone marrow-derived macrophages (BMDMs) (Figure 1a) were infected with concentrated Lenti-SP-green fluorescent protein (GFP) and Lenti-SP-LXRa viruses at a multiplicity of infection of 20. The cells were harvested and total RNA was isolated for reverse transcription, followed by conventional polymerase chain reaction (PCR) (Figure 1a ) and real-time PCR (Figures 1b, d and e). Enhanced expression of LXRa was observed in Lenti-SP-LXRa-infected cells, but not in Lenti-SP-GFP-infected cells or -uninfected control cells (Figures 1a and b) . Lenti-SP-LXRa expression at the protein level was confirmed by immunostaining in BMDM (Figure 1c) . To verify the specificity of transgene expression and exclude the possibility of LXRb compensation, LXRb mRNA levels were measured and showed very little difference between Lenti-SP-GFP-and Lenti-SP-LXRa-infected cells ( Figure 1b) . As ABCA1 (ATP-binding cassette, subfamily A, member 1) and ABCG1 are critical target genes of LXRs, 1 their expression was also studied in the presence or absence of LXR ligands. Lenti-SP-LXRa infection greatly enhanced ABCA1 (Figure 1d ) and ABCG1 (Figure 1e ) expression induced by LXRa agonist GW3965 or 22R-hydroxy cholesterol, whereas its inactive stereoisomer 22S-hydroxy cholesterol lacked any stimulatory effect. These data indicated that the LXRa transgene was biologically active.
Enhanced expression of LXRa in macrophages reduces the formation of atherosclerosis in LDLR À/À mice To determine the effect of LXRa on the formation of atherosclerotic lesions, wild-type C57BL/6J bone marrow cells infected with either Lenti-SP-GFP or Lenti-SP-LXRa were transplanted into lethally irradiated LDLR À/À mice. Wild-type mice were chosen as donors as donor blood cells from wild-type mice do not significantly impact atherosclerotic lesions when used to repopulate LDLR À/À mice. 14 The transduction and transplantation efficiency were high, as about 70% of monocytes/macrophages (CD11b+) in the peripheral blood expressed GFP strongly in the Lenti-SP-GFP mice at 12 weeks posttransplant, whereas less than 20% of CD11bÀ leukocytes expressed weak GFP (Figures 2a and b ) and erythrocytes were GFPÀ (data not shown), consistent with our previous report. 13 Animals were allowed to recover from the irradiation and transplant procedure for 4 weeks and were subsequently fed with a Western-type diet for 8 weeks before being killed for tissue collection. The sections of aortic root were stained with oil red O and quantified for lesion areas. Mice transplanted with Lenti-SP-LXRa-modified bone marrow showed a statistically significant 30% reduction in plaque size compared with the Lenti-SP-GFP group (Figures 2c-e) . Enhanced macrophage expression of LXRa was verified in the Lenti-SP-LXRa group as measured by quantitative reverse transcription (RT)-PCR (Figure 3a) . Using a polyclonal antibody, we did not show LXRa expression in the lesion areas (data not shown), in keeping with a report that the LXRa protein in the cell is very difficult to detect. 15 Enhanced expression of LXRa in macrophages increases expression of cholesterol efflux genes ABCA1 and apoE Because cholesterol reverse transport from macrophages in the aortic lesion sites is a critical mechanism for reducing local lipid content, we measured the expression of ABCA1, which is not only the key component in this process, but also a target gene of LXRs. 1 Increased expression levels of ABCA1 transcripts were shown in peritoneal macrophages ( Figure 3a ). Immunohistological analyses of atherosclerotic lesions ( Figure 3b ) showed increased ABCA1 protein in the lesions from Lenti-SP-LXRa mice compared with those from Lenti-SP-GFP mice. The higher levels of ABCA1 expression might contribute to the reduction of atherosclerotic lesion in this group of mice.
Because apoE is also a target gene of LXRs, 1, 16 we reasoned that overexpression of LXRa in macrophages might increase apoE expression and secretion and lead to the elevation of plasma apoE levels. As shown in Figure 4 , there was a significant 15% increase in plasma apoE levels of Lenti-SP-LXRa mice compared with those of Lenti-SP-GFP mice. Both ABCA1 and apoE mediate cellular cholesterol efflux from macrophages to extracellular acceptors, 17, 18 and their increased expression may contribute the observed amelioration of atherogenesis. Furthermore, the elevation of apoE levels in blood might play a role in lowering plasma triglyceride levels (see below).
Enhanced expression of LXRa in macrophages decreases plasma triglyceride levels Hyperlipidemia is a major risk factor for cardiovascular disease and a strong determinant of atherogenesis. To test whether the reduction in atherosclerosis was related to alteration of the plasma lipid levels, blood samples were collected and total cholesterol and triglyceride levels were measured. Although the total cholesterol levels in Lenti-SPLXRa mice showed a modest nonsignificant reduction, the triglyceride levels in Lenti-SP-LXRa mice were approximately 50% reduced compared with those in Lenti-SP-GFP mice ( Figure 5 ). The decreased levels of plasma triglycerides may contribute to the reduction of atherosclerosis, as triglyceride-rich lipoproteins have been shown to be independent risk predictors for this disease. 19 Enhanced expression of LXRa in macrophages decreases plasma levels of tumor necrosis factor-a and interleukin-6 There is increasing evidence that LXRs are also involved in the regulation of cytokine production in addition to control of lipid metabolism. Administration of LXR agonists inhibits the production of nitric oxide and the pro-inflammatory cytokines interleukin (IL)-1b, IL-6 and TNFa. 20 LXR-null mice display increased IL-6 and TNFa levels in vivo, 20 both of which may exacerbate atherosclerosis. 21, 22 To assess the role of these cytokines in our model, we compared the IL-6 and TNFa levels in the plasma between the two groups of animals. Although both IL-6 and TNFa were present in measurable levels (16-29.3 pg ml À1 plasma) in the control Lenti-SP-GFP mice, they were undetectable in the plasma of the majority of Lenti-SP-LXRa mice. These results suggest that the overexpression of LXRa in this model led to the reduction of pro-inflammatory cytokines, which in turn contributed to the observed reduction in atheromatous plaque. Moreover, decrease in TNFa levels might also be protective to the artery by lowing plasma triglyceride levels, as reported previously. 23 
DISCUSSION
Although LXRs are promising targets for the treatment of atherosclerosis, systematic delivery of an agonist induces triglyceride synthesis in the liver and poses a potential risk of worsening the disease. In addition, LXR agonists upregulate cholesteryl ester transfer protein, which functions in the plasma to lower the concentration of highdensity lipoprotein-C by moving cholesteryl esters from high-density lipoprotein to LDL, thus leading to the elevation of LDL cholesterol levels in human beings. 2 In this study, we show that macrophagespecific expression of an LXRa transgene in LDLR À/À mice can ameliorate atherosclerosis, while avoiding the adverse side effects associated with systematic delivery of LXR agonists, namely elevation of blood triglycerides due to increased hepatic synthesis. 24 Transplantation of bone marrow cells containing hematopoietic stem cells (HSCs) transduced with lentiviral vectors carrying a synthetic macrophage promoter-driving expression of the mouse LXRa cDNA caused a significant reduction of both atherosclerotic lesions and plasma triglyceride levels through expression of the transgene in BMDMs. These results are consistent with the observation that loss of LXR expression in bone marrow and peripheral blood cells increases atherosclerosis, 5 supporting the notion that the macrophage is a primary vehicle for the antiatherogenic effects of LXR, and showing the therapeutic potential of delivery of LXR via HSC-derived macrophages.
A new report reached similar conclusions through a different approach. 25 The authors generated transgenic mice with macrophage overexpression of LXRa driven by chicken lysozyme promoter and crossed them onto the LDLR À/À background. Atherosclerotic lesion area at the brachiocephalic artery was significantly reduced (83%) in these male LXRa transgenic mice, but not at aortic root and in female mice. It is unclear as to what caused these anatomical and gender differences in their study. Furthermore, unlike our study, these investigators did not observe a significant difference in plasma triglycerides between transgenic animals and non-transgenic controls, 25 presumably due to residual liver expression of the LXRa transgene in their experiments.
A primary function of LXRs in macrophages is to maintain cellular cholesterol homeostasis. Activation of LXRs in lipid-loaded macrophages causes induction of genes involved in the cholesterol efflux pathway in an attempt to reduce the intracellular cholesterol burden. The ABC transporters such as ABCA1 and ABCG1, functioning as a cholesterol efflux pump in the cellular lipid removal pathway, are critical for LXR-regulated cholesterol efflux to its acceptors. 1 LXRs are unable to stimulate cholesterol efflux to lipid-poor lipoproteins in cells from Tangier disease (ABCA1-deficient) patients. 24 LXRs are essential for lipid-inducible ABCA1 expression, as induction is lost in macrophages from LXRab À/À mice. This induction is due to the presence of LXR response elements in the proximal promoter of the ABCA1 gene. 26 In this study, we first showed in vitro that expression of both ABCA1 and ABCG1 was elevated in the LXRa-infected BMDMs, and then showed that enhanced expression of LXRa in macrophages in vivo led to increased expression of ABCA1 in both peritoneal macrophages and lesion areas of aorta. The increased levels of ABCA1 expression in macrophages may contribute to the observed reduction of the atherosclerotic lesions.
An additional mechanism that may operate in LXR-driven reverse cholesterol transport is the induction of a subset of apolipoproteins that may serve as cholesterol acceptors. 18 In this study, plasma apoE levels were elevated in mice that overexpressed LXRa in macrophages. The elevated apoE might have contributed to the observed decrease in levels of plasma triglycerides. ApoE facilitates cellular cholesterol efflux from macrophage foam cells and entering the plasma as well as participates in lipoprotein clearance. In addition, locally produced apoE in the atherosclerotic lesion areas could exert another known protective function, namely regulation of macrophage-and lymphocyte-mediated chronic inflammatory responses. 17 ApoE expression is modified by and also modifies both T-lymphocyte and macrophage cytokine production, 17 and thus appears to exert a direct influence on both the innate and acquired immune responses that are a part of this chronic inflammatory disease.
Considerable evidence indicates that, in addition to inducing genes involved in reverse cholesterol transport, LXRs reciprocally repress a set of inflammatory genes after bacterial, lipopolysaccharide or cytokine stimulation. 20 LXR ligands repress these genes in macrophages derived from wild-type, LXRa -/-, and LXRb -/-mice, but are unable to do so in macrophages from LXRa/b -/-mice. Among these inflammatory genes are IL-6 and TNFa, both of which enhance the development of atherosclerosis. 22 IL-6 induces production of monocyte chemoattractant protein-1, an important adhesion molecule that enhances macrophage accumulation in arterial wall fatty streaks. 27 TNFa increases monocyte recruitment and LDL oxidation, and thus accelerates atherogenesis. 28 Moreover, decreases in TNFa levels might also protect the arterial wall by lowering plasma triglyceride levels. 23 Our data show that LXRa-modified bone marrow transplantation could lower the IL-6 and TNFa levels in plasma and these changes might be responsible in part for the amelioration of atherogenesis.
A most interesting observation in this study was the reduction of plasma triglycerides after enhanced macrophage expression of LXRa. Systemic delivery of LXR ligands causes elevation of plasma triglycerides, mainly due to LXRa-induced hepatic sterol regulatoryelement-binding protein-1c expression, which leads to an increase in lipogenesis in the liver. 24 By increasing LXRa activity selectively in macrophages, the sterol regulatory-element-binding protein1c-mediated induction of triglyceride production in the liver should not be altered, providing an explanation for the absence of an increase in plasma triglycerides. Furthermore, both increased apoE and decreased TNFa in blood may play a role in lowering plasma triglycerides. Low plasma triglycerides eventually should contribute to inhibition of atherosclerotic lesion formation. 19 In summary, using a potentially clinic-translatable approach, we show that targeted macrophage overexpression of LXRa not only decreased atherosclerotic lesion formation, but also reduced plasma triglycerides, a major obstacle to date in LXR-based therapy of atherosclerosis. Owing to the continuous advances in HSC (and induced pluripotent stem-HSC) transplantation and gene delivery, 29, 30 HSC-based lentiviral LXR gene therapy may provide a valuable option for prevention and treatment for coronary heart disease and stroke, the major clinical manifestations of atherosclerosis.
MATERIALS AND METHODS
Cell culture
The 293T and RAW 264.7 cells were cultured in Dulbecco's modified Eagle's media (Invitrogen Inc., Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. For mouse BMDMs, marrow cells collected from femurs and tibias were cultured in Dulbecco's modified Eagle's media containing 10% fetal bovine serum, 20% horse serum and 20% L929 cell-conditioned medium for 7 days. 31 22R-hydroxy cholesterol, 22S-hydroxy cholesterol and GW3965 were purchased from Sigma Chemical Co. (St Louis, MO, USA). Peritoneal macrophages were obtained by lavage with 5 ml of ice-cold RPMI 1640 (Invitrogen) supplemented with 2 mM L-alanyl-L-glutamine, 1% (V V À1 ) non-essential amino acids and penicillin/streptomycin (100 U l À1 and 100 mg ml À1 , respectively). The cells were incubated for 4 h and non-adherent cells were then removed by washing with medium. The adherent macrophages were used for analysis. 32 
Plasmid and virus preparation
Murine LXRa cDNA (kindly provided by Ronald M Evans, The Salk Institute for Biological Studies, San Diego, CA, USA) was inserted into Lenti-SP-GFP plasmid 13 to replace the GFP coding sequence. These HIV-1-based lentiviral vectors contain central polypurine tract, central termination sequence and woodchuck hepatitis virus post-transcriptional regulatory element are depleted of accessory proteins tat, vrf, vpr, nef and vpu, and utilize self-inactivating long terminal repeat. They belong to the third-generation lentiviral system and are pseudotyped with vesicular stomatitis virus envelope protein. In addition, a synthetic macrophage promoter described previously 13 is incorporated in these vectors. Viruses were prepared as described previously. 13, 33 Briefly, plasmid Lenti-SP-LXRa or Lenti-SP-GFP with packaging plasmids pMDLg/ pRRE, pRSV/Rev and pMD.G was co-transfected into 293T cells in a ratio of 10:6:1.5:2.5. The media containing viruses were harvested at 36 and 72 h posttransfection, filtered through 0.45-mm pore size filters, and then concentrated 1000-fold by two rounds of centrifugation at 56 000 g for 120 min and at 68 000 g for 90 min. Viral pellets were resuspended in StemPro-34 SFM (Invitrogen) and stored at À80 1C for subsequent use. The titers of GFPexpressing lentiviral particles determined by infection in HeLa cells using the end-point dilution method 34 were between 10 8 and 10 9 IU ml À1 . LXRaexpressing lentiviral particle production was monitored by parallel production and titer determination of GFP-expressing lentiviral particles.
Bone marrow cell transduction and transplantation
Bone marrow cells obtained from C57BL/6J female mice (Jackson Laboratory, Bar Harbor, ME, USA) injected intravenously 4 days in advance with 5-fluoruracil (110 mg kg À1 ) were enriched for HSCs in the lymphocyte layer by gradient centrifugation using Lymphocyte-M (Cedarlane, Hornby, Ontario, Canada) and maintained overnight in StemPro-34 SFM medium containing 6 ng ml À1 of murine IL-3, 10 ng ml À1 of human IL-6, 10 ng ml À1 of murine IL-1a and 100 ng ml À1 of murine stem cell factor. 13, 35 The cells were then exposed to concentrated viruses in a small volume (B0.8 ml) of the same medium in a retronectin-coated well for 5 h. Eight week-old female LDLR À/À mice (Jackson Laboratory) were irradiated (950 cGy) with a cesium g-source and then injected with 3Â10 6 transduced cells via tail vein 6 h later. All mouse studies were performed with the approval of the University of Texas Health Science Center at San Antonio Institutional Animal Care and Use Committee.
Development of atherosclerosis and lesion analysis
At 4 weeks post-transplant, the recipients were placed on an atherogenic diet (TD96121:21% fat, 1.25% cholesterol; Harlan-Texlad, Madison, WI, USA) for 8 weeks before lesion analysis. The animals were anesthetized with ketamine HCl and then perfused after blood sample collection via the left ventricle with 15 ml cold phosphate-buffered saline (PBS) containing 1 mM EDTA and 30 ml fixative (PBS containing 4% paraformaldehyde and 5% sucrose) in sequence. Cells separated from heparinized blood were processed for fluorescence-activated cell sorting analysis. 13 The heart, along with the aortic root, was dissected, fixed overnight, embedded in OCT medium and then frozen. Frozen sections were cut 10 mm thick, starting from the beginning of the aortic sinus and continuing distally. Atherosclerotic lesions were identified by oil red O staining and counterstaining with hematoxylin. The mean lesion area for each animal was determined in five sections taken every 40 mm through the aortic valve. Quantification of lesion area was performed using the Spot 3.5.5 software (Diagnostic Instruments, Sterling Heights, MI, USA) and reported as mean mm 2 per section.
Immunohistochemistry
Standard avidin-Biotin complex method was employed to localize ABCA1 in 10-mm-thick frozen sections of aorta. Briefly, sections dried at room temperature for 30 min were washed in PBS and treated with 0.3% hydrogen peroxide to inhibit endogenous peroxidase activity. The sections were washed again in PBS for 15 min and incubated in 1% bovine serum albumin in PBS containing 0.3% Triton X-100 (blocking solution). Sections were then incubated with rabbit polyclonal antibody against ABCA1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; Cat. no. SC-20794) at 1:50 dilution overnight at 4 1C. Sections were rinsed in PBS for 10 min and incubated with biotinylated goat anti-rabbit secondary antibody for 40 min, followed by ABC (Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA). 3-Amino-9-ethyl carbazole (Sigma-Aldrich, St Louis, MO, USA) was used as chromogen to visualize the reaction product; reddish-brown precipitate indicated the presence of ABCA1 in the tissue sections. Sections were washed in distilled water and mounted in glycerol gelatin.
For immunofluorescence staining, bone-marrow-derived macrophages transduced with either Lenti-SP-LXRa or Lenti-SP-GFP were incubated with goat polyclonal antibody against LXRa/b (1:100 dilution; Santa Cruz Biotechnology, Cat no. SC-1201) overnight at 4 1C. Cells were rinsed in PBS for 10 min and incubated with donkey anti-goat secondary antibody conjugated with Alexa Fluor 568 (1:200; Molecular Probes, Carlsbad, CA, USA) for 40 min at room temperature. Fluorescent images were captured with a regular fluorescent microscope (Nikon Eclipse TE2000-U; Nikon Instruments Inc., Melville, NY, USA). Stringent control procedures were employed to ensure specificity of immunostaining.
RT-PCR and real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse transcribed using iScript cDNA synthesis Kit (Bio-Rad Laboratory, Hercules, CA, USA). The synthesized cDNA was used as template for conventional PCR and real-time PCR analysis. The primer sequences for conventional PCR were designed as follows: LXRa, sense (S): 5¢-CTGCCCAGCAACAGTGTAAC-3¢, antisense (A): 5¢-CTGCTTTGGCAAAGTCTTCCC-3¢; ABCA1, S: 5¢-CCCAGA GCAAAAAGCGACTC-3¢, A: 5¢-GGTCATCATCACTTTGGTCCTTG-3¢; 36B4, S: 5¢-TCATCCAGCAGGTGTTTGACA-3¢, S: 5¢-GGCACCGAGGCAACAGTT-3¢. The primer sequences of real-time PCR (SYBR green) were as follows: LXRa, S: 5¢-TGGGATGTCCACGAGTGACTGTTT-3¢, A: 5¢-TCCCTTAATGCTACGG AAGGCTCT-3¢; ABCA1, S: 5¢-GCAAGGCTACCAATTACATTTG-3¢, A: 5¢-GG TCAGAAACATCACCTCCTG-3¢; ABCG1, S: 5¢-ACCTACCACAACCCAGCAG ACTTT-3¢, A: 5¢-GGTGCCAAAGAAACGGGTTCACAT-3¢; b-actin, S: 5¢-GAT CTGGCACCACACCTTCT-3¢, A: 5¢-GGGGTGTTGAAGGTCTCAAA-3¢. SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) was used for real-time PCR performed on an Applied Biosystems Sequence Detector 7900HT system. The results were analyzed by the SDS RQ manager software and the specificity of the amplicons was verified by dissociation curve analysis.
Western blot
One microliter of plasma was diluted to 20 ml with PBS and 10 ml of 3Â loading buffer was added. The samples were boiled for 5 min, resolved on 12% sodium dodecyl sulfate polyacrylamide gels, and then blotted onto nitrocellulose membranes. The polyclonal goat anti-apoE antibody (Santa Cruz Biotechnology) was used at dilution of 1:500, and immunoreactive bands were visualized by an enhanced chemiluminescence kit (Pierce Biotechnology, Rockford, IL, USA) following reaction with horseradish peroxidase-conjugated rabbit anti-goat antibodies (1:10 000 dilution).
Lipid measurement
Plasma cholesterol and triglyceride were determined by enzymatic assay following the supplier's protocols (Thermo DMA, Arlington, TX, USA and Thermo Trace, Melbourne, Australia).
Quantification of TNFa and IL-6 in plasma
TNF-a and IL-6 levels in plasma were determined by enzyme-linked immunosorbent assay as described by the manufacturer (OptEIA Sets, Pharmingen, San Diego, CA, USA). Their concentrations in plasma were determined from authentic standards containing known concentrations of the proteins.
Statistical analysis
All numerical data are expressed as mean ± s.e.m., except real-time PCR data, which are expressed as the mean±s.d. Differences between values were analyzed using Mann-Whitney test (for the difference in atherosclerosis) or Student's t-test, and a probability value of Po0.05 was considered statistically significant.
